Skip to Main Content

Paper Details

Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Acta Neurochir (Wien)
4
2022
Author NameAffiliation
Hao PanJinling Hospital, Nanjing University
  • 1 - 1

Datasets

Release 1.2